References
- Adams, G. P. and Weiner, L. M. (2005) Monoclonal antibody therapy of cancer. Nat. Biotechnol. 23, 1147-1157 https://doi.org/10.1038/nbt1137
- Jang, S. H., Wientjes, M. G., Lu, D. and Au, J. L. (2003) Drug delivery and transport to solid tumors. Pharm. Res. 20, 1337-1350 https://doi.org/10.1023/A:1025785505977
- Beckman, R. A., Weiner, L. M. and Davis, H. M. (2007) Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumors. Cancer 109, 170-179 https://doi.org/10.1002/cncr.22402
- Graff, C. P. and Wittrup, K. D. (2003) Theoretical analysis of antibody targeting of tumor spheroids: importance of dosage for penetration, and affinity for retention. Cancer Res. 63, 1288-1296
- Kortt, A. A., Dolezal, O., Power, B. E. and Hudson, P. J. (2001) Dimeric and trimeric antibodies: high avidity scFvs for cancer targeting. Biomol. Eng. 18, 95-108 https://doi.org/10.1016/S1389-0344(01)00090-9
- Holt, L. J., Herring, C., Jespers, L. S., Woolven, B. P. and Tomlinson, I. M. (2003) Domain antibodies: proteins for therapy. Trends Biotechnol. 21, 484-490 https://doi.org/10.1016/j.tibtech.2003.08.007
- Qiu, X. Q., Wang, H., Cai, B., Wang, L. L. and Yue, S. T. (2007) Small antibody mimetics comprising two complementarity- determining regions and a framework region for tumor targeting. Nat. Biotechnol. 25, 921-929 https://doi.org/10.1038/nbt1320
- Ladner, R. C. (2007) Antibodies cut down to size. Nat. Biotechnol. 25, 875-877 https://doi.org/10.1038/nbt0807-875
- Casset, F., Roux, F., Mouchet, P., Bes, C., Chardes, T., Granier, C., Mani, J. C., Pugnière, M., Laune, D., Pau, B., Kaczorek, M., Lahana, R. and Rees, A. (2003) A peptide mimetic of an anti-CD4 monoclonal antibody by rational design. Biochem. Biophys. Res. Commun. 307, 198-205 https://doi.org/10.1016/S0006-291X(03)01131-8
- Qin, W., Feng, J., Li, Y., Lin, Z. and Shen, B. (2006) Fusion protein of CDR mimetic peptide with Fc inhibit TNF-a induced cytotoxicity. Mol. Immunol. 43, 660-666 https://doi.org/10.1016/j.molimm.2005.04.009
- Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A. and McGuire, W. L. (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177-182 https://doi.org/10.1126/science.3798106
- Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E. (1989) Studies of the HER-2/neu proto- oncogene in human breast and ovarian cancer. Science 244, 707-712 https://doi.org/10.1126/science.2470152
- Press, M. F., Bernstein, L., Thomas, P. A., Meisner, L. F., Zhou, J. Y., Ma, Y. (1997) HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J. Clin. Oncol. 15, 2894-2904 https://doi.org/10.1200/JCO.1997.15.8.2894
- Press, M. F., Slamon, D. J., Flom, K. J., Park, J., Zhou, J. Y. and Bernstein, L. (2002) Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J. Clin. Oncol. 20, 3095-3105 https://doi.org/10.1200/JCO.2002.09.094
- Jurado, P., de Lorenzo, V. and Fernández, L. A. (2006) Thioredoxin fusions increase folding of single chain Fv antibodies in the cytoplasm of Escherichia coli: evidence that chaperone activity is the prime effect of thioredoxin. J. Mol. Biol. 357, 49-61 https://doi.org/10.1016/j.jmb.2005.12.058
- Adams, G. P., Schier, R., McCall, A. M., Simmons, H. H., Horak, E. M., Alpaugh, R. K., Marks, J. D. and Weiner, L. M. (2001) High affinity restricts the localization and tumor penetration of single-chain Fv antibody molecules. Cancer Res. 61, 4750-4755
- Carter, P., Presta, L., Gorman, C. M., Ridgway, J. B., Henner, D., Wong, W. L., Rowland, A. M., Kotts, C., Carver, M. E. and Shepard, H. M. (1992) Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc. Natl. Acad. Sci. U.S.A. 89, 4285-4289 https://doi.org/10.1073/pnas.89.10.4285
- Li, B., Wang, H., Da, i. J., Ji, J., Qian, W., Zhang, D., Hou, S. and Guo, Y. (2005) Construction and characterization of a humanized anti-human CD3 monoclonal antibody 12F6 with effective immunoregulation functions. Immunology 116, 487-498
- Gao, J., Kou, G., Chen, H., Wang, H., Li, B., Lu, Y., Zhang, D., Wang, S., Hou, S., Qian, W., Dai, J., Zhao, J., Zhong, Y. and Guo, Y. (2008) Treatment of hepatocellular carcinoma in mice with PE38KDEL type I mutant-loaded poly(lactic-co-glycolic acid) nanoparticles conjugated with humanized SM5-1 F(ab’) fragments. Mol. Cancer Ther. 7, 3399-3407 https://doi.org/10.1158/1535-7163.MCT-08-0514
- Kou, G., Gao, J., Wang, H., Chen, H., Li, B., Zhang, D., Wang, S., Hou, S., Qian, W., Dai, J., Zhong, Y. and Guo, Y. (2007) Preparation and characterization of paclitaxelloaded PLGA nanoparticles coated with cationic SM5-1 single-chain antibody. J. Biochem. Mol. Biol. 40, 731-739 https://doi.org/10.5483/BMBRep.2007.40.5.731
- Li, B., Shi, S., Qian, W., Zhao, L., Zhang, D., Hou, S., Zheng, L., Dai, J., Zhao, J., Wang, H. and Guo, Y. (2008) Development of novel tetravalent anti-CD20 antibodies with potent antitumor activity. Cancer Res. 68, 2400-2408 https://doi.org/10.1158/0008-5472.CAN-07-6663
Cited by
- Development and Analytical Validation of a BT-474 Anti-Proliferation Assay Targeting HER2 vol.45, pp.12, 2012, https://doi.org/10.1080/00032719.2012.677787
- Antibody mimetics: promising complementary agents to animal-sourced antibodies vol.36, pp.2, 2016, https://doi.org/10.3109/07388551.2014.958431